Results 21 to 30 of about 231 (96)

OR21-04 Long-term Efficacy And Safety Of Once-weekly Somatrogon In Pediatric Subjects With Growth Hormone Deficiency: Results From Up To 8 Years Of Somatrogon Treatment [PDF]

J Endocr Soc, 2023
Abstract Disclosure: Z. Zadik: None. N. Zelinska: Consulting Fee; Self; Novo Nordisk, Berlin-Chemie, Medtronic, Sanofi-Aventis. Research Investigator; Self; MacroGenics, Novo Nordisk, Pfizer, Inc., Merck, OPKO Health, Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Parexel, Genexine. Speaker; Self; Medtronic, Berlin-Chemie,
Zadik, Zvi, Zelinska, Nataliya, Iotova, Violeta, Skorodok, Yulia, Malievskiy, Oleg A, Mauras, Nelly, Valluri, Srinivas R, Pastrak, Aleksandra, Rosenfeld, Ron G, Taylor, Carrie T, Nijher, Monica, Roland, Carl, Wang, Ronnie, Wajnrajch, Michael P, Cara, Jose F   +14 more
europepmc   +2 more sources

A Randomized, Cross‐Over Study Investigating the Comparability of Somatrogon‐ghla in 2 Different Drug Product Presentations

Clinical Pharmacology in Drug Development
Abstract Somatrogon‐ghla is a long‐acting, recombinant human growth hormone approved for the treatment of pediatric patients with growth hormone deficiency. Forty‐nine healthy, adult males were enrolled in a randomized, crossover study to compare somatrogon exposure after subcutaneous doses administered using a frozen vial presentation or a prefilled ...
Allison Manners, Joan Korth‐Bradley, Michael P. Wajnrajch   +2 more
exaly   +2 more sources

Pharmacovigilance evaluation of somatrogon-associated adverse events in real-world databases

Endocrine Connections
Background: Somatrogon, a long-acting recombinant human growth hormone, is used in children with growth hormone deficiency. While clinical trials have shown its safety, real-world post-marketing data are limited, and uncommon or delayed adverse events ...
Mengyuan Cai, Qian Guo, Huqiang Dong, Yabo Wang, Zhongyu Han, Ping Xu   +5 more
doaj   +2 more sources

Weekly Growth Hormone Somatrogon and Clinical Use Principles

Güncel Pediatri
The recombinant human growth hormone has been used for about 40 years and is administered as a single daily dose. Long-acting growth hormones are developed to enhance therapy adherence and reduce therapy load.
Erdal Eren, Furkan Erdoğan
doaj   +2 more sources

Commentary on "Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations" [PDF]

Annals of Pediatric Endocrinology & Metabolism
Yoo-Mi Kim
doaj   +2 more sources

Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study [PDF]

Journal of the Endocrine Society, 2022
Mehul Dattani, Aristides Maniatis, Gnanagurudasan Prakasam   +2 more
exaly   +2 more sources

What do we do now that the long-acting growth hormone is here?

Frontiers in Endocrinology, 2022
In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone ...
Bradley S. Miller
doaj   +1 more source

Growth hormone receptor agonists and antagonists: From protein expression and purification to long‐acting formulations

Protein Science, Volume 32, Issue 9, September 2023., 2023
Abstract Recombinant human growth hormone (rhGH) and GH receptor antagonists (GHAs) are used clinically to treat a range of disorders associated with GH deficiency or hypersecretion, respectively. However, these biotherapeutics can be difficult and expensive to manufacture with multiple challenges from recombinant protein generation through to the ...
Yue Wang, Minah Kim, Chantal Buckley, Heather D. Maynard, Ries J. Langley, Jo K. Perry   +5 more
wiley   +1 more source

Long‐acting growth hormone in 2022

Pediatric Investigation, Volume 7, Issue 1, Page 36-42, March 2023., 2023
After successful clinical use of growth hormone (GH) for nearly 70 years, we are now able to use long‐acting GH (LAGH) with identical or even slightly greater efficacy in clinical medicine in GH deficiency in children and adults. ABSTRACT After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the ...
Margaret Steiner, Jacklyn Frank, Paul Saenger   +2 more
wiley   +1 more source

Metformin—‘BRAINS & AIMS’ pharmacological/prescribing principles of commonly prescribed (Top 100) drugs: Education and discussion

British Journal of Clinical Pharmacology, Volume 89, Issue 3, Page 931-938, March 2023., 2023
We review pharmacological/prescribing principles relating to metformin according to our mnemonic framework: ‘BRAINS & AIMS’ (Benefits, Risks, Adverse Effects, Interactions, Necessary prophylaxis, Susceptibilities, Administering, Informing, Monitoring and Stopping): Benefits: Metformin's licensed uses: Type 2 diabetes mellitus (T2DM) treatment ...
Joshua Koslover, Deborah Bruce, Shivani Patel, Andrew J. Webb   +3 more
wiley   +1 more source